Benitec's InterfRx licence options have to have gone up in value if analysts are re-rating Alny as a buy. We've got 5 - got to be somewhere between $10M to $50M each, i'd have thought the latter given Alny's breakthrough clinical data.
Also worth noting the Alny 5x15 programme does not have a single disease target that conflicts with Benitec programme.
http://community.nasdaq.com/News/2011-11/alnylam-reveals-alnttr01-trial-data-analyst-blog.aspx?storyid=104992
- Forums
- ASX - By Stock
- BLT
- alny interfrx options
alny interfrx options
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)